CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Determine which index fund delivers stronger rolling returns using straightforward comparisons and key performance signals.
28,161 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
SpaceX is courting attention ahead of a potential Nasdaq debut. Some ETFs offer pre-IPO exposure via SPVs, but the st...
When the world's biggest ethereum treasury buys the dip, it grabs headlines—and raises questions for everyday investo...
Entrepreneurship powered America’s rise, and Steve Case argues we must expand that engine nationwide to guard the cou...
A growing number of retirees are choosing to stay in Chicago, turning a local lifestyle into a cost-saving retirement...
Ethereum faces near-term headwinds, but a rebound may follow a deeper pullback. This analysis translates Standard Cha...
A major cold storage leader caught the eye of a notable investor, who disclosed a fresh stake worth $19 million. This...
A rising iPhone upgrade cycle is quietly lifting a little-known stock. This article breaks down why the move makes it...
Netflix stock has slipped from its mid-2025 highs, now flirting with a 52-week low. This article explains what that m...
FRP Holdings delivered a resilient Q3 2024 performance across its diversified subsidiaries. This deep dive reviews th...
A timely tribute to Ted Turner and the daring moves that built a media empire. From billboard prince to cable mogul, ...
A midcareer parent confronts a stark choice: borrow to fund a child's college or protect a dwindling retirement. Expe...